{"id":"W4405050504","doi":"10.1016/j.esmoop.2024.103972","title":"Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Foundation Medicine; XBiotech; EMD Serono; Genentech; National Institutes of Health; HCA Healthcare; Pfizer; Incyte; Moderna; Revolution Medicines; Gilead Sciences; National Cancer Institute; Vertex Pharmaceuticals; F. Hoffmann-La Roche; Eli Lilly and Company; AstraZeneca; Jounce Therapeutics; Celgene; Array BioPharma; Astellas Pharma; TG Therapeutics; Seagen; Agios Pharmaceuticals","keywords":"Atezolizumab; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Oncology; Medicine; Urothelial cancer; Internal medicine; Urology; Phase (matter); Bladder cancer; Cancer; Chemistry; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00432218,0.0009593656,0.001518016,0.000221098,0.0002362115,0.001195832,0.0006829033,0.0008559389,0.001934656],"category_scores_gemma":[0.002565901,0.0002558029,0.001831173,0.0003692172,0.0003522566,0.0006020413,0.0004519972,0.001780473,0.0004497225],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005901643,"about_ca_system_score_gemma":0.0007598765,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003123685,"about_ca_topic_score_gemma":0.001150463,"domain_scores_codex":[0.9988625,0.0007484755,0.00004987878,0.0001295859,0.0001063152,0.0001032322],"domain_scores_gemma":[0.9982311,0.0004512157,0.0004818816,0.0002443126,0.0001240349,0.0004675958],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8121758,0.004754739,0.04288717,0.002264337,0.008304054,0.000370369,0.0002102884,0.004772604,0.009088376,0.0004802787,0.02198422,0.09270774],"study_design_scores_gemma":[0.720461,0.1084566,0.1403672,0.0004272236,0.007075978,0.001073426,0.0001285647,0.004561455,0.002587495,0.0009848354,0.0137675,0.0001087045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9755337,0.01110678,0.0007291036,0.001156154,0.000165872,0.00100969,0.006656775,0.0001090982,0.003533009],"genre_scores_gemma":[0.9807658,0.00262692,0.0008985748,0.001124066,0.0001600602,0.0009790016,0.01218755,0.00003879807,0.001219372],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00432218,"threshold_uncertainty_score":0.0228582,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0958352596985449,"score_gpt":0.4042303405836028,"score_spread":0.3083950808850579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}